Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease

Current Topics in Medicinal Chemistry

Volumn 13, Issue 15, 2013, Pages 1808-1819

  Martinez, Ana ^a   Perez, Daniel I ^a   Gil, Carmen ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

Alzheimer's disease; Clinical trials; Drug design; GSK 3 inhibitors; Neurodegenerative diseases

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 4 BENZYL 2 METHYL 1,2,4 THIADIAZOLIDINE 3,5 DIONE; AR A 04418; BIO; BIP 135; CESI; CHIR 98023; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; L803 MTS; LITHIUM; NP 031115; PLACEBO; SC 001; TAU PROTEIN; TDZD 8; THIADIAZOLE DERIVATIVE; TIDEGLUSIB; UNCLASSIFIED DRUG; VALPROIC ACID; VP 0 7; VP 2 51;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; BLOOD BRAIN BARRIER; BRAIN ATROPHY; BRAIN DEVELOPMENT; CARCINOGENESIS; DENTATE GYRUS; DRUG DESIGN; ENZYME BINDING; HUMAN; IC 50; LEARNING DISORDER; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHASE 2 CLINICAL TRIAL(TOPIC); PROTEIN PHOSPHORYLATION; REVIEW;

ALZHEIMER DISEASE; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DESIGN; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; NOOTROPIC AGENTS;

EID: 84887972830     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113139990138     Document Type: Review

References (125)

1. Lassmann, H.; Fischer, P.; Jellinger, K. Synaptic pathology of Alzheimer's disease. Ann. N. Y. Acad. Sci, 1993, 695, 59-64.
2. Stefanacci, R. G. The costs of Alzheimer's disease and the value of effective therapies. Am. J. Manag. Care, 2011, 17 (Suppl 13), S356-S362.
3. Mayeux, R.; Stern, Y. Epidemiology of Alzheimer disease. Cold Spring Harb. Perspect. Med, 2012, 2, doi: 10. 1101/cshperspect. a006239.
4. Marques, S. C.; Oliveira, C. R.; Outeiro, T. F.; Pereira, C. M. Alzheimer's disease: the quest to understand complexity. J. Alzheimers Dis, 2010, 21, 373-383.
5. Raina, P.; Santaguida, P.; Ismaila, A.; Patterson, C.; Cowan, D.; Levine, M.; Booker, L.; Oremus, M. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann. Intern. Med, 2008, 148, 379-397.
6. Bartus, R. T.; Dean, R. L., 3rd; Beer, B.; Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science, 1982, 217, 408-414.
7. Schneider, L. S.; Tariot, P. N. Emerging drugs for Alzheimer's disease. Mechanisms of action and prospects for cognitive enhancing medications. Med. Clin. North Am, 1994, 78, 911-934.
8. Shanks, M.; Kivipelto, M.; Bullock, R.; Lane, R. Cholinesterase inhibition: is there evidence for disease-modifying effects? Curr. Med. Res. Opin, 2009, 25, 2439-2446.
9. Selkoe, D. J. Alzheimer's disease: genotypes, phenotypes, and treatments. Science, 1997, 275, 630-631.
10. Armstrong, R. A. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease. Folia Neuropathol, 2009, 47, 289-299.
11. Saumier, D.; Duong, A.; Haine, D.; Garceau, D.; Sampalis, J. Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study. J. Nutr. Health Aging, 2009, 13, 808-812.
12. Vellas, B. Tarenflurbil for Alzheimer's disease: a "shot on goal" that missed. Lancet Neurol, 2010, 9, 235-237.
13. Schor, N. F. What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us. Ann. Neurol, 2011, 69, 237-239.
14. Tayeb, H. O.; Murray, E. D.; Price, B. H.; Tarazi, F. I. Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive? Expert Opin. Biol. Ther, 2013, doi: 10. 1517/14712598. 14712013. 14789856.
15. Dodel, R.; Rominger, A.; Bartenstein, P.; Barkhof, F.; Blennow, K.; Forster, S.; Winter, Y.; Bach, J. P.; Popp, J.; Alferink, J.; Wiltfang, J.; Buerger, K.; Otto, M.; Antuono, P.; Jacoby, M.; Richter, R.; Stevens, J.; Melamed, I.; Goldstein, J.; Haag, S.; Wietek, S.; Farlow, M.; Jessen, F. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol, 2013, 12, 233-243.
16. Montañes, M.; Casabona, D.; Sarasa, L.; Pesini, P.; Sarasa, M. Prevention of amyloid-beta fibril formation using antibodies against the C-terminal region of amyloid-beta1-40 and amyloidbeta1-42. J. Alzheimers Dis, 2013, 34, 133-137.
17. Moreth, J.; Mavoungou, C.; Schindowski, K. Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immun. Ageing, 2013, 10, doi: 10. 1186/1742-4933-1110-1118.
18. Iqbal, K.; Grundke-Iqbal, I. Molecular mechanism of Alzheimer's neurofibrillary degeneration and therapeutic intervention. Ann. N. Y. Acad. Sci, 1996, 777, 132-138.
19. Wischik, C.; Staff, R. Challenges in the conduct of diseasemodifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. J. Nutr. Health Aging, 2009, 13, 367-369.
20. del Ser, T.; Steinwachs, K. C.; Gertz, H. J.; Andres, M. V.; Gomez-Carrillo, B.; Medina, M.; Vericat, J. A.; Redondo, P.; Fleet, D.; Leon, T. Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. J. Alzheimers Dis, 2013, 33, 205-215.
21. Imahori, K.; Hoshi, M.; Ishiguro, K.; Sato, K.; Takahashi, M.; Shiurba, R.; Yamaguchi, H.; Takashima, A.; Uchida, T. Possible role of tau protein kinases in pathogenesis of Alzheimer's disease. Neurobiol. Aging, 1998, 19, S93-S98.
22. Plattner, F.; Angelo, M.; Giese, K. P. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem, 2006, 281, 25457-25465.
23. Hooper, C.; Killick, R.; Lovestone, S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem, 2008, 104, 1433-1439.
24. Muyllaert, D.; Kremer, A.; Jaworski, T.; Borghgraef, P.; Devijver, H.; Croes, S.; Dewachter, I.; Van Leuven, F. Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology? Genes Brain Behav, 2008, 7 Suppl 1, 57-66.
25. Jolivalt, C. G.; Lee, C. A.; Beiswenger, K. K.; Smith, J. L.; Orlov, M.; Torrance, M. A.; Masliah, E. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J. Neurosci. Res, 2008, 86, 3265-3274.
26. de la Monte, S. M.; Tong, M.; Lester-Coll, N.; Plater, M., Jr.; Wands, J. R. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J. Alzheimers Dis, 2006, 10, 89-109.
27. Leroy, K.; Yilmaz, Z.; Brion, J. P. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol. App. Neurobiol, 2007, 33, 43-55.
28. DaRocha-Souto, B.; Coma, M.; Perez-Nievas, B. G.; Scotton, T. C.; Siao, M.; Sanchez-Ferrer, P.; Hashimoto, T.; Fan, Z.; Hudry, E.; Barroeta, I.; Sereno, L.; Rodriguez, M.; Sanchez, M. B.; Hyman, B. T.; Gomez-Isla, T. Activation of glycogen synthase kinase-3 beta mediates beta-amyloid induced neuritic damage in Alzheimer's disease. Neurobiol. Dis, 2012, 45, 425-437.
29. Dewachter, I.; Ris, L.; Jaworski, T.; Seymour, C. M.; Kremer, A.; Borghgraef, P.; De Vijver, H.; Godaux, E.; Van Leuven, F. GSK3beta, a centre-staged kinase in neuropsychiatric disorders, modulates long term memory by inhibitory phosphorylation at serine-9. Neurobiol. Dis, 2009, 35, 193-200.
30. Wang, H.; Brown, J.; Martin, M. Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine, 2011, 53, 130-140.
31. Martinez, A.; Perez, D. I. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J. Alzheimers Dis, 2008, 15, 181-191.
32. Embi, N.; Rylatt, D. B.; Cohen, P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem, 1980, 107, 519-527.
33. Kaidanovich-Beilin, O.; Woodgett, J. R. GSK-3: Functional insights from cell biology and animal models. Front. Mol. Neurosci, 2011, 4, doi: 10. 3389/fnmol. 2011. 00040.
34. Jope, R. S.; Johnson, G. V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci, 2004, 29, 95-102.
35. Takahashi, M.; Tomizawa, K.; Kato, R.; Sato, K.; Uchida, T.; Fujita, S. C.; Imahori, K. Localization and developmental changes of tau protein kinase I/glycogen synthase kinase-3 beta in rat brain. J. Neurochem, 1994, 63, 245-255.
36. Takahashi-Yanaga, F. Activator or Inhibitor? GSK-3 as a new drug target. Biochem. Pharmacol, 2013, doi: 10. 1016/j. bcp. 2013. 1004. 1022.
37. Mines, M. A. Hyperactivity: Glycogen synthase kinase-3 as a therapeutic target. Eur. J. Pharmacol, 2013, 708, 56-59.
38. Koros, E.; Dorner-Ciossek, C. The role of glycogen synthase kinase-3beta in schizophrenia. Drug News Perspect, 2007, 20, 437-445.
39. Naito, S.; Bilim, V.; Yuuki, K.; Ugolkov, A.; Motoyama, T.; Nagaoka, A.; Kato, T.; Tomita, Y. Glycogen synthase kinase-3beta: a prognostic marker and a potential therapeutic target in human bladder cancer. Clin. Cancer Res, 2010, 16, 5124-5132.
40. Bilim, V.; Ougolkov, A.; Yuuki, K.; Naito, S.; Kawazoe, H.; Muto, A.; Oya, M.; Billadeau, D.; Motoyama, T.; Tomita, Y. Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br. J. Cancer, 2009, 101, 2005-2014.
41. Garcea, G.; Manson, M. M.; Neal, C. P.; Pattenden, C. J.; Sutton, C. D.; Dennison, A. R.; Berry, D. P. Glycogen synthase kinase-3 beta; a new target in pancreatic cancer? Curr. Cancer Drug Targets, 2007, 7, 209-215.
42. Martinez, A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med. Res. Rev, 2008, 28, 773-796.
43. Ahn, S. W.; Kim, J. E.; Park, K. S.; Choi, W. J.; Hong, Y. H.; Kim, S. M.; Kim, S. H.; Lee, K. W.; Sung, J. J. The neuroprotective effect of the GSK-3beta inhibitor and influence on the extrinsic apoptosis in the ALS transgenic mice. J. Neurol. Sci, 2012, 320, 1-5.
44. Guo, W.; Murthy, A. C.; Zhang, L.; Johnson, E. B.; Schaller, E. G.; Allan, A. M.; Zhao, X. Inhibition of GSK3beta improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Hum. Mol. Genet, 2012, 21, 681-691.
45. Rosa, A. O.; Kaster, M. P.; Binfare, R. W.; Morales, S.; Martin-Aparicio, E.; Navarro-Rico, M. L.; Martinez, A.; Medina, M.; Garcia, A. G.; Lopez, M. G.; Rodrigues, A. L. Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32, 1549-1556.
46. Kaidanovich-Beilin, O.; Milman, A.; Weizman, A.; Pick, C. G.; Eldar-Finkelman, H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol. Psychiatry, 2004, 55, 781-784.
47. Beurel, E.; Kaidanovich-Beilin, O.; Yeh, W. I.; Song, L.; Palomo, V.; Michalek, S. M.; Woodgett, J. R.; Harrington, L. E.; Eldar-Finkelman, H.; Martinez, A.; Jope, R. S. Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3. J. Immunol, 2013, 190, 5000-5011.
48. Jones, K.; Wei, C.; Iakova, P.; Bugiardini, E.; Schneider-Gold, C.; Meola, G.; Woodgett, J.; Killian, J.; Timchenko, N. A.; Timchenko, L. T. GSK3beta mediates muscle pathology in myotonic dystrophy. J. Clin. Invest, 2012, 122, 4461-4472.
49. Mazzardo-Martins, L.; Martins, D. F.; Stramosk, J.; Cidral-Filho, F. J.; Santos, A. R. Glycogen synthase kinase 3-specific inhibitor AR-A014418 decreases neuropathic pain in mice: evidence for the mechanisms of action. Neuroscience, 2012, 226, 411-420.
50. Martins, D. F.; Rosa, A. O.; Gadotti, V. M.; Mazzardo-Martins, L.; Nascimento, F. P.; Egea, J.; Lopez, M. G.; Santos, A. R. The antinociceptive effects of AR-A014418, a selective inhibitor of glycogen synthase kinase-3 beta, in mice. J. Pain, 2011, 12, 315-322.
51. Morales-Garcia, J. A.; Susin, C.; Alonso-Gil, S.; Perez, D. I.; Palomo, V.; Perez, C.; Conde, S.; Santos, A.; Gil, C.; Martinez, A.; Perez-Castillo, A. Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. ACS Chem. Neurosci, 2013, 4, 350-360.
52. Cuzzocrea, S.; Genovese, T.; Mazzon, E.; Crisafulli, C.; Di Paola, R.; Muia, C.; Collin, M.; Esposito, E.; Bramanti, P.; Thiemermann, C. Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma. J. Pharmacol. Exp. Ther, 2006, 318, 79-89.
53. Tuncdemir, M.; Yildirim, A.; Karaoglan, A.; Akdemir, O.; Ozturk, M. AR-A014418 as a glycogen synthase kinase-3 inhibitor: Antiapoptotic and therapeutic potential in experimental spinal cord injury. Neurocirugia (Astur), 2013, 24, 22-32.
54. Chen, P. C.; Gaisina, I. N.; El-Khodor, B. F.; Ramboz, S.; Makhortova, N. R.; Rubin, L. L.; Kozikowski, A. P. Identification of a maleimide-based glycogen synthase kinase-3 (GSK-3) inhibitor, BIP-135, that prolongs the dedian survival time of delta7 SMA KO mouse model of spinal muscular atrophy. ACS Chem. Neurosci, 2012, 3, 5-11.
55. Zhou, X.; Zhou, J.; Li, X.; Guo, C.; Fang, T.; Chen, Z. GSK-3beta inhibitors suppressed neuroinflammation in rat cortex by activating autophagy in ischemic brain injury. Biochem. Biophys. Res. Commun, 2011, 411, 271-275.
56. Collino, M.; Thiemermann, C.; Mastrocola, R.; Gallicchio, M.; Benetti, E.; Miglio, G.; Castiglia, S.; Danni, O.; Murch, O.; Dianzani, C.; Aragno, M.; Fantozzi, R. Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus. Shock, 2008, 30, 299-307.
57. Cline, G. W.; Johnson, K.; Regittnig, W.; Perret, P.; Tozzo, E.; Xiao, L.; Damico, C.; Shulman, G. I. Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes, 2002, 51, 2903-2910.
58. Kaidanovich-Beilin, O.; Eldar-Finkelman, H. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. J. Pharmacol. Exp. Ther, 2006, 316, 17-24.
59. Rao, R.; Hao, C. M.; Redha, R.; Wasserman, D. H.; McGuinness, O. P.; Breyer, M. D. Glycogen synthase kinase 3 inhibition improves insulin-stimulated glucose metabolism but not hypertension in high-fat-fed C57BL/6J mice. Diabetologia, 2007, 50, 452-460.
60. Lee, S.; Yang, W. K.; Song, J. H.; Ra, Y. M.; Jeong, J. H.; Choe, W.; Kang, I.; Kim, S. S.; Ha, J. Anti-obesity effects of 3-hydroxychromone derivative, a novel small-molecule inhibitor of glycogen synthase kinase-3. Biochem. Pharmacol, 2013, 85, 965-976.
61. Cuzzocrea, S.; Mazzon, E.; Di Paola, R.; Muia, C.; Crisafulli, C.; Dugo, L.; Collin, M.; Britti, D.; Caputi, A. P.; Thiemermann, C. Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin. Immunol, 2006, 120, 57-67.
62. Whittle, B. J.; Varga, C.; Posa, A.; Molnar, A.; Collin, M.; Thiemermann, C. Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta. Br. J. Pharmacol, 2006, 147, 575-582.
63. Gurrieri, C.; Piazza, F.; Gnoato, M.; Montini, B.; Biasutto, L.; Gattazzo, C.; Brunetta, E.; Cabrelle, A.; Cinetto, F.; Niero, R.; Facco, M.; Garbisa, S.; Calabrese, F.; Semenzato, G.; Agostini, C. 3-(2, 4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2, 5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosis. J. Pharmacol. Exp. Ther, 2010, 332, 785-794.
64. Cuzzocrea, S.; Malleo, G.; Genovese, T.; Mazzon, E.; Esposito, E.; Muia, C.; Abdelrahman, M.; Di Paola, R.; Thiemermann, C. Effects of glycogen synthase kinase-3beta inhibition on the development of cerulein-induced acute pancreatitis in mice. Crit. Care Med, 2007, 35, 2811-2821.
65. Cuzzocrea, S.; Genovese, T.; Mazzon, E.; Esposito, E.; Muia, C.; Abdelrahman, M.; Di Paola, R.; Bramanti, P.; Thiemermann, C. Glycogen synthase kinase-3beta inhibition attenuates the development of bleomycin-induced lung injury. Int. J. Immunopathol. Pharmacol, 2007, 20, 619-630.
66. Bao, Z.; Lim, S.; Liao, W.; Lin, Y.; Thiemermann, C.; Leung, B. P.; Wong, W. S. Glycogen synthase kinase-3beta inhibition attenuates asthma in mice. Am. J. Respir. Crit. Care Med, 2007, 176, 431-438.
67. Song, E. Y.; Palladinetti, P.; Klamer, G.; Ko, K. H.; Lindeman, R.; O'Brien, T. A.; Dolnikov, A. Glycogen synthase kinase--3beta inhibitors suppress leukemia cell growth. Exp. Hematol, 2010, 38, 908-921 e901.
68. Aguilar-Morante, D.; Morales-Garcia, J. A.; Sanz-SanCristobal, M.; Garcia-Cabezas, M. A.; Santos, A.; Perez-Castillo, A. Inhibition of glioblastoma growth by the thiadiazolidinone compound TDZD-8. PLoS One, 2010, 5, e13879.
69. Gunn, W. G.; Krause, U.; Lee, N.; Gregory, C. A. Pharmaceutical inhibition of glycogen synthetase kinase-3beta reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model. Blood, 2011, 117, 1641-1651.
70. Zhu, Q.; Yang, J.; Han, S.; Liu, J.; Holzbeierlein, J.; Thrasher, J. B.; Li, B. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate, 2011, 71, 835-845.
71. Hoeflich, K. P.; Luo, J.; Rubie, E. A.; Tsao, M. S.; Jin, O.; Woodgett, J. R. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature, 2000, 406, 86-90.
72. O'Brien, W. T.; Harper, A. D.; Jove, F.; Woodgett, J. R.; Maretto, S.; Piccolo, S.; Klein, P. S. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci, 2004, 24, 6791-6798.
73. Kaidanovich-Beilin, O.; Lipina, T. V.; Takao, K.; van Eede, M.; Hattori, S.; Laliberte, C.; Khan, M.; Okamoto, K.; Chambers, J. W.; Fletcher, P. J.; MacAulay, K.; Doble, B. W.; Henkelman, M.; Miyakawa, T.; Roder, J.; Woodgett, J. R. Abnormalities in brain structure and behavior in GSK-3alpha mutant mice. Mol. Brain, 2009, 2, 35 (doi: 10. 1186/1756-6606-1182-1135).
74. Alon, L. T.; Pietrokovski, S.; Barkan, S.; Avrahami, L.; Kaidanovich-Beilin, O.; Woodgett, J. R.; Barnea, A.; Eldar-Finkelman, H. Selective loss of glycogen synthase kinase-3alpha in birds reveals distinct roles for GSK-3 isozymes in tau phosphorylation. FEBS Lett, 2011, 585, 1158-1162.
75. Lucas, J. J.; Hernandez, F.; Gomez-Ramos, P.; Moran, M. A.; Hen, R.; Avila, J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J, 2001, 20, 27-39.
76. Hernandez, F.; Borrell, J.; Guaza, C.; Avila, J.; Lucas, J. J. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J. Neurochem, 2002, 83, 1529-1533.
77. Fuster-Matanzo, A.; Llorens-Martin, M.; de Barreda, E. G.; Avila, J.; Hernandez, F. Different susceptibility to neurodegeneration of dorsal and ventral hippocampal dentate gyrus: a study with transgenic mice overexpressing GSK3beta. PLoS One, 2011, 6, e27262.
78. Sirerol-Piquer, M.; Gomez-Ramos, P.; Hernandez, F.; Perez, M.; Moran, M. A.; Fuster-Matanzo, A.; Lucas, J. J.; Avila, J.; Garcia-Verdugo, J. M. GSK3beta overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. Hippocampus, 2011, 21, 910-922.
79. Phiel, C. J.; Wilson, C. A.; Lee, V. M.; Klein, P. S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature, 2003, 423, 435-439.
80. Pearce, N. J.; Arch, J. R.; Clapham, J. C.; Coghlan, M. P.; Corcoran, S. L.; Lister, C. A.; Llano, A.; Moore, G. B.; Murphy, G. J.; Smith, S. A.; Taylor, C. M.; Yates, J. W.; Morrison, A. D.; Harper, A. J.; Roxbee-Cox, L.; Abuin, A.; Wargent, E.; Holder, J. C. Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3beta on a muscle-specific promoter. Metabolism, 2004, 53, 1322-1330.
81. Xu, C.; Kim, N. G.; Gumbiner, B. M. Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle, 2009, 8, 4032-4039.
82. Ali, A.; Hoeflich, K. P.; Woodgett, J. R. Glycogen synthase kinase-3: properties, functions, and regulation. Chem. Rev, 2001, 101, 2527-2540.
83. Bouskila, M.; Hirshman, M. F.; Jensen, J.; Goodyear, L. J.; Sakamoto, K. Insulin promotes glycogen synthesis in the absence of GSK3 phosphorylation in skeletal muscle. Am. J. Physiol. Endocrinol. Metab, 2008, 294, E28-E35.
84. Avrahami, L.; Licht-Murava, A.; Eisenstein, M.; Eldar-Finkelman, H. GSK-3 inhibition: Achieving moderate efficacy with high selectivity. Biochim. Biophys. Acta, 2013, doi: 10. 1016/j. bbapap. 2013. 1001. 1016.
85. Woodgett, J. R. In Glycogen synthase kinase 3 (GSK-3) and its inhibitors. Martinez, A., Castro, A. and Medina, M., Ed.; John Wiley & Sons: Hoboken, New Jersey, 2006, pp 3-23.
86. Woodgett, J. R. cDNA cloning and properties of glycogen synthase kinase-3. Methods Enzymol, 1991, 200, 564-577.
87. Eldar-Finkelman, H.; Martinez, A. GSK-3 inhibitors: Preclinical and clinical focus on CNS. Front. Mol. Neurosci, 2011, 4, doi: 10. 3389/fnmol. 2011. 00032.
88. Onishi, T.; Iwashita, H.; Uno, Y.; Kunitomo, J.; Saitoh, M.; Kimura, E.; Fujita, H.; Uchiyama, N.; Kori, M.; Takizawa, M. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S)-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1, 3, 4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease. J. Neurochem, 2011, 119, 1330-1340.
89. Sereno, L.; Coma, M.; Rodriguez, M.; Sanchez-Ferrer, P.; Sanchez, M. B.; Gich, I.; Agullo, J. M.; Perez, M.; Avila, J.; Guardia-Laguarta, C.; Clarimon, J.; Lleo, A.; Gomez-Isla, T. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol. Dis, 2009, 35, 359-367.
90. Noh, M. Y.; Chun, K.; Kang, B. Y.; Kim, H.; Park, J. S.; Lee, H. C.; Kim, Y. H.; Ku, S.; Kim, S. H. Newly developed glycogen synthase kinase-3 (GSK-3) inhibitors protect neuronal cells death in amyloid-beta induced cell model and in a transgenic mouse model of Alzheimer's disease. Biochem. Biophys. Res. Commun, 2013, doi: 10. 1016/j. bbrc. 2013. 1004. 1065.
91. Uno, Y.; Iwashita, H.; Tsukamoto, T.; Uchiyama, N.; Kawamoto, T.; Kori, M.; Nakanishi, A. Efficacy of a novel, orally active GSK-3 inhibitor 6-methyl-N-[3-[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice. Brain Res, 2009, 1296, 148-163.
92. Gong, E. J.; Park, H. R.; Kim, M. E.; Piao, S.; Lee, E.; Jo, D. G.; Chung, H. Y.; Ha, N. C.; Mattson, M. P.; Lee, J. Morin attenuates tau hyperphosphorylation by inhibiting GSK3beta. Neurobiol. Dis, 2011, 44, 223-230.
93. Georgievska, B.; Sandin, J.; Doherty, J.; Mortberg, A.; Neelissen, J.; Andersson, A.; Gruber, S.; Nilsson, Y.; Schott, P.; Arvidsson, P. I.; Hellberg, S.; Osswald, G.; Berg, S.; Falting, J.; Bhat, R. V. AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. J. Neurochem, 2013, 125, 446-456.
94. Caccamo, A.; Oddo, S.; Tran, L. X.; LaFerla, F. M. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am. J. Pathol, 2007, 170, 1669-1675.
95. Noble, W.; Planel, E.; Zehr, C.; Olm, V.; Meyerson, J.; Suleman, F.; Gaynor, K.; Wang, L.; LaFrancois, J.; Feinstein, B.; Burns, M.; Krishnamurthy, P.; Wen, Y.; Bhat, R.; Lewis, J.; Dickson, D.; Duff, K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. U. S. A, 2005, 102, 6990-6995.
96. Garcia, I.; Fall, Y.; Gomez, G. QSAR, docking, and CoMFA studies of GSK3 inhibitors. Curr. Pharm. Des, 2010, 16, 2666-2675.
97. Saitoh, M.; Kunitomo, J.; Kimura, E.; Iwashita, H.; Uno, Y.; Onishi, T.; Uchiyama, N.; Kawamoto, T.; Tanaka, T.; Mol, C. D.; Dougan, D. R.; Textor, G. P.; Snell, G. P.; Takizawa, M.; Itoh, F.; Kori, M. 2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1, 3, 4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta with good brain permeability. J. Med. Chem, 2009, 52, 6270-6286.
98. Arfeen, M.; Bharatam, P. V. Design of glycogen synthase kinase-3 inhibitors: An overview on recent advancements. Curr. Pharm. Des, 2012, in press.
99. Bamborough, P.; Drewry, D.; Harper, G.; Smith, G. K.; Schneider, K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J. Med. Chem, 2008, 51, 7898-7914.
100. Eglen, R.; Reisine, T. Drug discovery and the human kinome: recent trends. Pharmacol. Ther, 2011, 130, 144-156.
101. McInnes, C.; Fischer, P. M. Strategies for the design of potent and selective kinase inhibitors. Curr. Pharm. Des, 2005, 11, 1845-1863.
102. Palomo, V.; Soteras, I.; Perez, D. I.; Perez, C.; Gil, C.; Campillo, N. E.; Martinez, A. Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. J. Med. Chem, 2011, 54, 8461-8470.
103. Martinez, A.; Alonso, M.; Castro, A.; Perez, C.; Moreno, F. J. First non-ATP competitive glycogen synthase kinase 3 beta (GSK 3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem, 2002, 45, 1292-1299.
104. Dominguez, J. M.; Fuertes, A.; Orozco, L.; del Monte-Millan, M.; Delgado, E.; Medina, M. Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J. Biol. Chem, 2012, 287, 893-904.
105. Belani, C. P. The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. Cancer Invest, 2010, 28, 413-423.
106. Conde, S.; Perez, D. I.; Martinez, A.; Perez, C.; Moreno, F. J. Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching. J. Med. Chem, 2003, 46, 4631-4633.
107. Perez, D. I.; Conde, S.; Perez, C.; Gil, C.; Simon, D.; Wandosell, F.; Moreno, F. J.; Gelpi, J. L.; Luque, F. J.; Martinez, A. Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. Bioorg. Med. Chem, 2009, 17, 6914-6925.
108. Perez, D. I.; Palomo, V.; Perez, C.; Gil, C.; Dans, P. D.; Luque, F. J.; Conde, S.; Martinez, A. Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. J. Med. Chem, 2011, 54, 4042-4056.
109. Eldar-Finkelman, H.; Licht-Murava, A.; Pietrokovski, S.; Eisenstein, M. Substrate competitive GSK-3 inhibitors-strategy and implications. Biochim. Biophys. Acta, 2010, 1804, 598-603.
110. Eldar-Finkelman, H.; Eisenstein, M. Peptide inhibitors targeting protein kinases. Curr. Pharm. Des, 2009, 15, 2463-2470.
111. Palomo, V.; Perez, D. I.; Perez, C.; Morales-Garcia, J. A.; Soteras, I.; Alonso-Gil, S.; Encinas, A.; Castro, A.; Campillo, N. E.; Perez-Castillo, A.; Gil, C.; Martinez, A. 5-Imino-1, 2, 4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. J. Med. Chem, 2012, 55, 1645-1661.
112. Hamann, M.; Alonso, D.; Martin-Aparicio, E.; Fuertes, A.; Perez-Puerto, M. J.; Castro, A.; Morales, S.; Navarro, M. L.; Del Monte-Millan, M.; Medina, M.; Pennaka, H.; Balaiah, A.; Peng, J.; Cook, J.; Wahyuono, S.; Martinez, A. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. J. Nat. Prod, 2007, 70, 1397-1405.
113. Zhang, P.; Hu, H. R.; Huang, Z. H.; Lei, J. Y.; Chu, Y.; Ye, D. Y. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg. Med. Chem. Lett, 2012, 22, 7232-7236.
114. Perez, D. I.; Pistolozzi, M.; Palomo, V.; Redondo, M.; Fortugno, C.; Gil, C.; Felix, G.; Martinez, A.; Bertucci, C. 5-Imino-1, 2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3beta (GSK-3beta) and phosphodiesterase 7 (PDE7) inhibitors: determination of blood-brain barrier penetration and binding to human serum albumin. Eur. J. Pharm. Sci, 2012, 45, 677-684.
115. Bidon-Chanal, A.; Fuertes, A.; Alonso, D.; Perez, D. I.; Martinez, A.; Luque, F. J.; Medina, M. Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. Eur. J. Med. Chem, 2013, 60, 479-489.
116. Stambolic, V.; Ruel, L.; Woodgett, J. R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol, 1996, 6, 1664-1668.
117. O'Brien, W. T.; Klein, P. S. Validating GSK3 as an in vivo target of lithium action. Biochem. Soc. Trans, 2009, 37, 1133-1138.
118. De Sarno, P.; Li, X.; Jope, R. S. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology, 2002, 43, 1158-1164.
119. Hampel, H.; Ewers, M.; Burger, K.; Annas, P.; Mortberg, A.; Bogstedt, A.; Frolich, L.; Schroder, J.; Schonknecht, P.; Riepe, M. W.; Kraft, I.; Gasser, T.; Leyhe, T.; Moller, H. J.; Kurz, A.; Basun, H. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J. Clin. Psychiatry, 2009, 70, 922-931.
120. Macdonald, A.; Briggs, K.; Poppe, M.; Higgins, A.; Velayudhan, L.; Lovestone, S. A feasibility and tolerability study of lithium in Alzheimer's disease. Int. J. Geriatr. Psychiatry, 2008, 23, 704-711.
121. Forlenza, O. V.; Diniz, B. S.; Radanovic, M.; Santos, F. S.; Talib, L. L.; Gattaz, W. F. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br. J. Psychiatry, 2011, 198, 351-356.
122. Nunes, M. A.; Viel, T. A.; Buck, H. S. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr. Alzheimer Res, 2013, 10, 104-107.
123. Corbett, A.; Pickett, J.; Burns, A.; Corcoran, J.; Dunnett, S. B.; Edison, P.; Hagan, J. J.; Holmes, C.; Jones, E.; Katona, C.; Kearns, I.; Kehoe, P.; Mudher, A.; Passmore, A.; Shepherd, N.; Walsh, F.; Ballard, C. Drug repositioning for Alzheimer's disease. Nat. Rev. Drug Discov, 2012, 11, 833-846.
124. Hoeglinger, G. Tideglusib, a GSK-3 inhibitor, reduces progression of brain atrophy in progressive supranuclear palsy. 2012, AAIC 2012; abstract O2014-2012-2002.
125. Thompson, P. A.; Wright, D. E.; Counsell, C. E.; Zajicek, J. Statistical analysis, trial design and duration in Alzheimer's disease clinical trials: a review. Int. Psychogeriatr, 2012, 24, 689-697.